The Risks of Using Semaglutide as a Fertility Aid: What You Need to Know

British Scientists Warn Against Using Semaglutide as Fertility Aid

British scientists have issued a warning about the potential risks of using semaglutide as a fertility aid, particularly during pregnancy. Semaglutide, a drug commonly used for Type 2 diabetes and weight loss, has been linked to unexpected pregnancies in some women, including those with fertility issues.

Anecdotal reports of so-called “Ozempic babies” have surfaced, with stories of women becoming pregnant while using semaglutide. While weight loss itself can improve fertility, experts caution that the effects of semaglutide on pregnancy and developing babies are still unknown.

Semaglutide, which mimics a hormone called glucagon-like peptide-1 (GLP-1), is known for its appetite-suppressing effects. Popular brands like Ozempic and Wegovy are not indicated as fertility treatments, and their packaging explicitly warns against use during pregnancy.

According to Nerys Astbury, a senior researcher in diet and obesity at the University of Oxford, weight loss can positively impact fertility by improving ovulation and egg release. However, the true impact of semaglutide on pregnancy and fertility conditions requires dedicated scientific research.

Experts emphasize the importance of stopping semaglutide use months before attempting to conceive and maintaining a balanced diet during pregnancy. Women taking semaglutide are advised to use contraception to prevent pregnancy while on the drug and to prioritize their nutritional health for the well-being of the developing baby.

In light of these warnings, it is crucial for healthcare providers to exercise caution when prescribing semaglutide and for women to prioritize their reproductive health when considering the use of this drug.